GlassScriptPhysician profile
Suneel Chilukuri
NPI 1578674305
$288,158.31
in general payments reported to CMS, 2019-2025
14 companies · $103K in 2025
The $103K reported for 2025 was more than what 99% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $14K · 2021: $29K · 2022: $46K · 2023: $17K · 2024: $15K · 2025: $103K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Consulting Fee: $33K · Food and Beverage: $5,778 · Travel and Lodging: $5,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $90,712.23 |
| Consulting Fee | $33,300.00 |
| Food and Beverage | $5,777.74 |
| Travel and Lodging | $5,445.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $128,858.21 | 2019-2022 | |
| Revance Therapeutics, INC. | $72,507.64 | 2024-2025 | Daxxify |
| Abbvie INC. | $38,307.92 | 2022-2025 | Botox |
| Galderma Laboratories, L.P. | $36,236.55 | 2019-2025 | Dysport, Aklief |
| Aclaris Therapeutics, INC. | $9,488.11 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,595.83 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Merz North America, INC. | $412.55 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $216.73 | 2022-2023 | Absorica Ld, Winlevi |
| Solta Medical, A Division of Bausch Health US, LLC | $164.58 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $143.12 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $66.73 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $62.02 | 2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $57.73 | 2023 | |
| Incyte Corporation | $40.59 | 2024 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suneel Chilukuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.